Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Omicron COVID-19 variant: What we know and should we worry?

by Reuters

Dec 15, 2021 - 9:36 am GMT+3
People queue to receive a dose of the COVID-19 vaccine at a vaccination center outside Guy's and St Thomas' Hospital in central London, U.K., Dec. 13, 2021. (AFP Photo)
People queue to receive a dose of the COVID-19 vaccine at a vaccination center outside Guy's and St Thomas' Hospital in central London, U.K., Dec. 13, 2021. (AFP Photo)
by Reuters Dec 15, 2021 9:36 am

First identified three weeks ago, the omicron variant of the coronavirus has now been detected in 77 countries, triggering panic worldwide. Concerns of a new, bigger wave of coronavirus cases mounting at hospitals, fears of accelerated infection rate and the possibility of evading vaccines – or protection from prior infections – due to its large number of mutations have pushed countries to be on high alert.

So, scientists have been working hard to figure out the ins and outs of the emergent variant as fast as possible, looking for answers to several key questions.

Is it more contagious?

The fast-spreading delta variant remains dominant worldwide, and it is unclear whether omicron is inherently more contagious than its predecessor, the World Health Organization (WHO) said in a statement on Sunday.

Early data suggests that the new variant is spreading faster than previous versions of the virus. In South Africa, the United Kingdom and Denmark, the number of new omicron infections has been doubling every two days at “an alarming rate of growth,” according to Dr. Eric Topol, director of the Scripps Research Translational Institute in California's La Jolla.

The omicron variant accounted for about 44% of infections in London on Monday and was expected to become the dominant version of the virus there within 48 hours.

What does it cause?

Scientists say it is still too early to know whether omicron causes more or less severe COVID-19 symptoms than previous versions of the virus.

In South Africa, scientists have said they see no sign that the omicron variant is causing more severe illness. Hospital data found that the COVID-19 admissions were rising sharply in more than half of the country's nine provinces, but there have been comparatively few deaths and indicators such as the median length of hospital stay have been reassuring.

Among the 43 people identified having the omicron variant in the United States, most reported mild symptoms, including coughing, congestion and fatigue.

People so far infected with omicron have largely reported mild illness likely because many have at least some immunity from vaccinations and/or prior infection.

A more clear picture of omicron's severity will come after analyzing outcomes for a larger number of infected people, particularly older, unvaccinated, previously uninfected patients.

Can it reinfect, evade inoculation?

The omicron variant has about 50 mutations not seen in combination before, including more than 30 mutations of the spike protein the coronavirus uses to attach to human cells. Most current COVID-19 vaccines target that spike protein, making the cluster of mutations potentially problematic.

In its latest report, the WHO said there were early signs that vaccinated and previously infected people would not build enough antibodies to ward off an infection from omicron.

A small study from a South African research institute suggested that omicron could partially evade protection from two doses of the Pfizer-BioNTech vaccine. The drugmaker BioNTech said a third booster dose of their vaccine was better able to neutralize omicron in the laboratory. These findings will need to be compared with how vaccinated people fare in the real world against omicron.

A U.K. government brief on Friday said early estimates suggest vaccine protection against symptomatic disease is significantly lower with omicron infection compared to the delta variant, although a booster dose led to vaccine effectiveness of 70% to 75% soon after the extra shot.

Are current treatments still effective?

Omicron's mutations are expected to reduce the effectiveness of certain manufactured antibody treatments, including some sold by Regeneron Pharmaceuticals and Eli Lilly & Co. Drugmaker GSK last week said its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology was effective against the omicron variant in lab tests.

Experimental antiviral pills – such as Pfizer Inc.'s Paxlovid and Merck & Co. Inc.'s molnupiravir – target parts of the virus that are not changed in omicron. These drugs are likely to become essential if vaccine-induced and natural immunity are threatened.

  • shortlink copied
  • Last Update: Dec 15, 2021 11:14 am
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 pandemic omicron variant delta variant covid-19 variants covid-19 treatment covid-19 vaccines
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    An amateur photographer Vincent Cornelissen captures a bean goose flying upside down. (Photo from Instagram @b0unce1971)

    It is showing off: Photographer captures goose flying upside down

    ANIMALS-ARCHIVES
    Parts of the newly completed last section of the Northern Marmara Motorway, Istanbul, Turkey, May 19, 2021. (DHA Photo)

    Turkey raises speed limits on highways starting from July

    SPEED-LIMIT

    Türkiye registers better-than-expected current account gap

    current-account-balance

    Istanbul's consulate chronicles: Sudhi Choudhary, Consul General of India

    SUDHI-CHOUDHARY
    No Image
    Makeshift camps, freezing cold: Migrants stuck at Poland-Belarus border
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021